Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oncobax AM
- Development stage
- Unknown
- Lead developer
- EverImmune
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Oncobax AM (also known as Oncobax AK) is an orally administered live biotherapeutic product (LBP) developed by EverImmune. It consists of a proprietary, lyophilized, and encapsulated single bacterial strain of *Akkermansia* (specifically *Akkermansia muciniphila* or *Akkermansia massiliensis* strain P2261). Oncobax AM is designed to act as an immunogenic commensal bacterium that restores or enhances patient responsiveness to immune checkpoint inhibitors (ICIs), such as PD-1/PD-L1 inhibitors, in patients with advanced solid tumors who are deficient in *Akkermansia*. It is currently being evaluated in Phase I/II clinical trials for the treatment of non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC).
- Other names
- Akkermansia Eve#01Akkermansia massiliensis strain p2261Akkermansia muciniphila strain P2261CSUR P2261Oncobax AKOncobax-AKOncobax-AMp2261p-2261p 2261
Beyond the preview
Go deeper on Oncobax AM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oncobax AM.